There are 2 papers on medication optimization score in aging research: 1 trial and 1 observational study in people.
2 papers study it2 findings
1 new paper in 30 daysSee all 2 papers on medication optimization score
“baseline MOS was associated with a lower hazard of the composite outcome (hazard ratio (HR) 0.96, 95% confidence interval (95% CI): 0.92, 0.99, p = 0.040)”
- Human trial1
- Humans1
Interventions
1Engage-hf
upin humans1
1 study
Engage-hf
upin humans1
Engage-hf increases medication optimization score in humans (83.7% vs. 74.0%; p = 0.010).
“At 90 days, the adjusted MOS was significantly higher in the ENGAGE-HF group compared to the control group (83.7% vs. 74.0%, p = 0.010).”
Human trialrecently hospitalized patients with heart failure, LVEF <50%, and suboptimal guideline-directed medical therapy; compared with usual carepatient-facing mobile app and clinician dashboard90 daysn = 134
Circulation. Heart failure
Associations
1Mortality or hospitalization
downin humans1HR 0.96
1 study
Mortality or hospitalization
downin humans1HR 0.96
Medication optimization score is linked with a lower risk of mortality or hospitalization in humans (chronic HFrEF, adjusted for HF severity and comorbidities) (HR 0.96 (95% CI: 0.92, 0.99), p = 0.040).
“baseline MOS was associated with a lower hazard of the composite outcome (hazard ratio (HR) 0.96, 95% confidence interval (95% CI): 0.92, 0.99, p = 0.040)”
Humanschronic HFrEF, adjusted for HF severity and comorbidities
Pharmacotherapy